Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
AbbVie (GB:0QCV)
LSE:0QCV
0QCV Stock Chart & Stats
Day’s Range― - ―
52-Week Range$153.53 - $208.50
Previous CloseN/A
Volume123.97K
Average Volume (3M)4.76K
Market Cap
$300.94B
Enterprise Value$413.77B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)59.5
Beta0.31
Next Earnings
Jan 31, 2025EPS Estimate
2.98Last Dividend Ex-Date
Jan 15, 2025Dividend Yield3.64%
Share Statistics
EPS (TTM)2.87
Shares Outstanding1,767,140,400
10 Day Avg. Volume211
30 Day Avg. Volume4,761
Standard Deviation0.10
R-Squared0.00552
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)5.42
Price to Cash Flow (P/CF)13.80
P/FCF Ratio13.10
Enterprise Value/Market Cap1.37
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit12.20
Enterprise Value/Ebitda17.07
Forecast
1Y Price Target
$207.30Price Target Upside6.99% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering20
---
Bulls Say, Bears Say
Bulls Say
Guidance And OutlookManagement provided encouraging 2027 guidance for Skyrizi & Rinvoq, stating that growth beyond 2027 is underappreciated by the Street.
Market PositionABBV is relatively well-positioned with a key strength being less patent expiry burden compared to others.
Revenue GrowthSkyrizi and Rinvoq's leading positions in I&I are getting stronger and should yield significant incremental profits for reinvestment.
Bears Say
Asset ImpairmentABBV will recognize a $3.5B impairment charge due to emraclidine failure.
Financial AdjustmentsRevenues and EPS for 2025/2026 are lower by 1-2% due to continued weakness in Aesthetics and delay in pipeline launches.
Pipeline ConcernsAbbVie's pipeline currently lacks late-stage mega-blockbusters.
---
Options Prices
Currently, No data available
---
Ownership Overview
0.08% Insiders
21.89% Mutual Funds
0.06% Other Institutional Investors
57.43% Public Companies and Individual Investors
0QCV FAQ
What was AbbVie’s price range in the past 12 months?
AbbVie lowest share price was $153.53 and its highest was $208.50 in the past 12 months.
What is AbbVie’s market cap?
AbbVie’s market cap is $300.94B.
When is AbbVie’s upcoming earnings report date?
AbbVie’s upcoming earnings report date is Jan 31, 2025 which is 7 days ago.
How were AbbVie’s earnings last quarter?
AbbVie released its earnings results on Jan 31, 2025. The company reported $2.16 earnings per share for the quarter, beating the consensus estimate of $2.115 by $0.045.
Is AbbVie overvalued?
According to Wall Street analysts AbbVie’s price is currently Undervalued.
Does AbbVie pay dividends?
AbbVie pays a Quarterly dividend of $6.286 which represents an annual dividend yield of 3.64%. See more information on AbbVie dividends here
What is AbbVie’s EPS estimate?
AbbVie’s EPS estimate is 2.98.
How many shares outstanding does AbbVie have?
AbbVie has 1,767,140,400 shares outstanding.
What happened to AbbVie’s price movement after its last earnings report?
AbbVie reported an EPS of $2.16 in its last earnings report, beating expectations of $2.115. Following the earnings report the stock price went up 5.09%.
Which hedge fund is a major shareholder of AbbVie?
Currently, no hedge funds are holding shares in GB:0QCV
---
AbbVie Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$207.30 (6.99% Upside)
$207.30 (6.99% Upside)
Blogger Sentiment
Bullish
GB:0QCV Sentiment 94%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $310.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
7.48%
12-Months-Change
Fundamentals
Return on Equity
56.06%
Trailing 12-Months
Asset Growth
5.29%
Trailing 12-Months
Company Description
AbbVie
AbbVie, Inc. is a biopharmaceutical company focused on key therapeutic areas like immunology, oncology, neuroscience, eye care, virology, women's health and gastroenterology. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.
---
0QCV Earnings Call
Q4 2025
0:00 / 0:00
Earnings Call Sentiment|Positive
AbbVie demonstrated strong financial performance in 2024 with notable growth in its ex-Humira platform and advancements in neuroscience and oncology. However, challenges persist with Humira revenue erosion and the aesthetic market facing economic headwinds. Overall, the company is poised for robust growth in 2025 despite these challenges.Read More>---
0QCV Net revenue Breakdown
48.12% Immunology
14.21% Neuroscience
12.59% Other Key Products
10.89% Oncology
14.19% Other
---
0QCV Stock 12 Month Forecast
Average Price Target
$207.30
▲(6.99% Upside)
Technical Analysis
Bristol-Myers Squibb
―
Eli Lilly & Co
―
Johnson & Johnson
―
Merck & Company
―
Pfizer
―
Best Analysts Covering 0QCV
1 Year
1 Year Success Rate
18/18 ratings generated profit
1 Year Average Return
+17.07%
reiterated a buy rating 5 days ago
Copying Mohit Bansal's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +17.07% per trade.
---